FDA Policy/General

Guidance Raises Expectations for Form 483 Responses, Expert Says

FDA’s recent draft guidance on Form-483 responses is signaling tougher expectations for how drug manufacturers respond to inspection observations, according to a regulatory affairs analysis published on clinicalleader.com by Rivka Zaibel of ADRES Bio.

The draft guidance, which outlines FDA expectations for responses following GMP inspections, emphasizes that companies must demonstrate operational control and systemic remediation rather than simply explain individual inspection findings, Zaibel wrote. “The companies that struggle most after a Form FDA 483 is issued are often not the ones that lack words,” Zaibel wrote. “They are the ones that lack control.”

According to the analysis, the draft guidance encourages manufacturers to conduct broader, risk-based investigations that examine whether deficiencies extend beyond the initially cited observation to related products, systems or manufacturing processes. The guidance also stresses the importance of detailed root-cause investigations, corrective and preventive action plans, interim controls and executive management involvement in remediation efforts.

Zaibel said FDA is making clear that weak investigations and narrow responses may signal broader quality-system failures to regulators.

The draft guidance also explicitly recognizes the potential role of outside consultants, particularly in cases involving data integrity concerns or broad systemic deficiencies.

Zaibel said the guidance is especially significant for companies operating in pre-approval settings, where inadequate responses could affect product review timelines and regulatory approvals.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome